Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M; Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Bachanova V, et al. Among authors: armand p. Biol Blood Marrow Transplant. 2015 Sep;21(9):1605-11. doi: 10.1016/j.bbmt.2015.05.007. Epub 2015 May 14. Biol Blood Marrow Transplant. 2015. PMID: 25983043 Free PMC article. Clinical Trial.
Allogeneic stem cell transplantation for aplastic anemia.
Armand P, Antin JH. Armand P, et al. Biol Blood Marrow Transplant. 2007 May;13(5):505-16. doi: 10.1016/j.bbmt.2007.02.005. Biol Blood Marrow Transplant. 2007. PMID: 17448909 Free article. Review.
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Armand P, et al. Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25. doi: 10.1016/j.bbmt.2008.01.008. Biol Blood Marrow Transplant. 2008. PMID: 18342784 Free PMC article.
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Cutler C, et al. Among authors: armand p. Blood. 2008 Dec 1;112(12):4425-31. doi: 10.1182/blood-2008-07-169342. Epub 2008 Sep 5. Blood. 2008. PMID: 18776081 Free PMC article.
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH. Armand P, et al. J Clin Oncol. 2008 Dec 10;26(35):5767-74. doi: 10.1200/JCO.2008.17.7279. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001324 Free PMC article.
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, Antin JH, Soiffer RJ, Alyea EP. Ho VT, et al. Among authors: armand p. Biol Blood Marrow Transplant. 2009 Jul;15(7):844-50. doi: 10.1016/j.bbmt.2009.03.017. Biol Blood Marrow Transplant. 2009. PMID: 19539216 Free PMC article. Clinical Trial.
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP 3rd. Koreth J, et al. Among authors: armand p. Blood. 2009 Oct 29;114(18):3956-9. doi: 10.1182/blood-2009-07-231092. Epub 2009 Aug 27. Blood. 2009. PMID: 19713456 Free PMC article. Clinical Trial.
315 results